Bristol Myers pulls plug on Reblozyl program for rare blood disorder, months after missed PDUFA date
Bristol Myers Squibb laid out some big plans over the last couple of years for its Celgene-acquired anemia drug Reblozyl, forecasting a $4 billion-plus peak …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
